Orforglipron Results: How Much Weight Can You Lose?

If you have been following the weight loss medication space, you will almost certainly have come across orforglipron — the oral GLP-1 receptor agonist developed by Eli Lilly that has been generating significant excitement among clinicians, researchers, and people living with obesity alike. Unlike semaglutide and tirzepatide, which require weekly injections, orforglipron is taken as a once-daily pill, and the clinical trial results emerging throughout 2025 and into 2026 suggest it could genuinely rival injectable treatments in terms of efficacy.

Quick Summary

Orforglipron is an investigational oral GLP-1 medication that has delivered impressive weight loss and blood glucose improvements in phase 3 trials. Here is what you need to know before diving into the full breakdown.

• Orforglipron produced up to approximately 9% body weight reduction in phase 3 ATTAIN-1 trial participants over 40 weeks
• It is taken as a once-daily tablet, making it a needle-free alternative to injections like Wegovy or Mounjaro
• The most common side effects mirror other GLP-1 medications: nausea, vomiting, and diarrhoea, which tend to be mild to moderate
• Regulatory approval in the UK and EU has not yet been confirmed as of mid-2026, though FDA submission is anticipated imminently
• It may be particularly suitable for people who are needle-averse or struggle with the administration demands of injectable treatments

Table of Contents

• What Is Orforglipron and How Does It Work?
• Orforglipron Results From Phase 3 Clinical Trials
• How Orforglipron Compares to Injectable GLP-1 Medications
• Side Effects and Safety Profile: What the Data Shows
• Who May Be Suitable for Orforglipron Treatment?
• UK Availability, Regulatory Status and What Comes Next
• Orforglipron Clinical Trial Data at a Glance
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• Frequently Asked Questions

What Is Orforglipron and How Does It Work?

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and liraglutide — both of which are peptide-based and must be injected because they would be broken down in the gut if swallowed — orforglipron has a chemical structure that allows it to survive the digestive process and be absorbed orally. This is what makes it fundamentally different from anything currently on the market for obesity in the UK.

To understand what that means in practice, it helps to know what GLP-1 actually does. To learn more about this hormone, you can read our detailed guide on GLP-1 meaning and what this hormone does in your body. In short, GLP-1 is a naturally occurring gut hormone released after eating. It signals to the brain that you are full, slows gastric emptying, stimulates insulin secretion, and suppresses glucagon — a hormone that raises blood sugar. Orforglipron mimics all of these effects in a tablet form.

The key pharmacological advantage of orforglipron is convenience. The medication must be taken on an empty stomach, with only plain water, and no food for at least 30 minutes afterward. While that is a minor inconvenience, it is far less burdensome for many people than weekly self-injection. For those who are needle-averse, who struggle with the injection site reactions associated with current weight loss treatments, or who simply find the routine of preparing and administering an injection difficult, this oral option represents a meaningful step forward.

• Taken once daily as a tablet — no mixing, no needles, no refrigeration required
• Acts on GLP-1 receptors in the brain, pancreas, and gut
• Reduces appetite, promotes satiety, and slows gastric emptying
• Has glucose-lowering effects relevant to both obesity and type 2 diabetes management
• Does not require cold chain storage, unlike current injectable GLP-1 medications

Orforglipron Results From Phase 3 Clinical Trials

The Orforglipron Results that have attracted the most attention come from the ATTAIN-1 phase 3 clinical trial, which evaluated the drug specifically for weight management in adults with obesity or overweight who did not have type 2 diabetes. The trial enrolled over 500 participants and ran across multiple international sites, with participants randomised to receive either orforglipron at doses of 12 mg, 24 mg, or 45 mg once daily, or placebo.

By week 26, participants on the 45 mg dose had achieved an average body weight reduction of approximately 7.9% from baseline. By week 40, that figure rose to around 9.4% in some analyses. To put that in perspective, a person weighing 100 kg at the start of the trial could expect to have lost roughly 9 to 9.5 kg over approximately nine months. These are clinically meaningful results, particularly given that the treatment was delivered orally without any injections.

Importantly, the results were not confined to weight loss alone. Participants also showed improvements in cardiometabolic risk markers including waist circumference, blood pressure, lipid profiles, and fasting glucose levels. The trial demonstrated a clear dose-response relationship — meaning that higher doses produced greater weight loss — though even the lowest 12 mg dose outperformed placebo significantly. A separate phase 3 trial in people with type 2 diabetes, ATTAIN-DM, also showed meaningful HbA1c reductions alongside weight loss.

• Average weight loss of up to 9.4% body weight over 40 weeks at the highest dose
• Statistically significant results across all three dose levels versus placebo
• Improvements in HbA1c, blood pressure, waist circumference, and lipid panels observed
• Results published and presented at major international diabetes and obesity conferences in 2025 and 2026
• Dropout rates were broadly comparable to other GLP-1 trials, suggesting acceptable tolerability

How Orforglipron Compares to Injectable GLP-1 Medications

This is where the nuance becomes important. Orforglipron does deliver impressive weight loss for an oral medication, but it is worth comparing it honestly with the results seen in injectable GLP-1 trials. Semaglutide 2.4 mg weekly (Wegovy) produced an average body weight reduction of around 14.9% over 68 weeks in the STEP 1 trial. Tirzepatide (Mounjaro) achieved up to 20.9% body weight reduction at the highest dose over 72 weeks in the SURMOUNT-1 trial.

So in raw efficacy terms, orforglipron at 9% weight loss over 40 weeks sits below the headline numbers of both Mounjaro tirzepatide and Wegovy semaglutide. However, it is not quite as simple as saying orforglipron is less effective. First, the trial durations differ significantly — 40 weeks versus 68 to 72 weeks. Weight loss with GLP-1 medications continues to accrue over time, and longer trials may show additional loss. Second, not everyone can or wants to inject themselves weekly. For that population, orforglipron at 9% weight loss is dramatically better than no treatment or a less effective oral alternative.

There is also an oral semaglutide formulation (Rybelsus), but it is only licensed for type 2 diabetes management and produces far more modest weight loss than injectable semaglutide. Orforglipron, by contrast, is being developed explicitly for obesity management as well as diabetes, and its efficacy in the obesity indication far exceeds that of Rybelsus. For people curious about how different injectable options compare, our comparison of GLP-1 agonists for type 2 diabetes is a useful companion read.

• Orforglipron: ~9% weight loss over 40 weeks (oral, once daily)
• Wegovy semaglutide: ~14.9% weight loss over 68 weeks (weekly injection)
• Mounjaro tirzepatide: up to ~20.9% weight loss over 72 weeks (weekly injection)
• Oral semaglutide (Rybelsus): modest weight loss, licensed only for type 2 diabetes
• Orforglipron does not require refrigeration or needles — a significant practical advantage

Side Effects and Safety Profile: What the Data Shows

Any honest assessment of orforglipron results must address safety and tolerability alongside efficacy. The good news is that the side effect profile observed in ATTAIN-1 and related trials broadly mirrors what is already well understood from other GLP-1 medications. The most frequently reported adverse events were gastrointestinal in nature — nausea, vomiting, diarrhoea, and constipation — and these were generally described as mild to moderate in severity.

Nausea was the most common complaint, reported by a higher proportion of participants on orforglipron than on placebo, particularly during the dose escalation phase. This is consistent with the GLP-1 drug class and tends to improve over time as the body adjusts. Dose escalation is typically managed gradually over several weeks precisely to minimise these effects. In the ATTAIN-1 trial, treatment discontinuation due to adverse events was higher in the orforglipron group than placebo, but within ranges seen in other GLP-1 trials. To understand whether these types of effects are expected on GLP-1 therapy, our guide on understanding side effects when starting GLP-1 treatment is worth reading.

One important safety consideration that has been raised in the context of GLP-1 drugs broadly is the potential for muscle mass loss alongside fat loss. This is relevant with orforglipron too, and people on the treatment are generally advised to maintain adequate protein intake and engage in resistance exercise where possible. Our resource on whether GLP-1s like Mounjaro cause muscle loss explores this in more depth. No new or unexpected safety signals emerged from the phase 3 data reviewed to date in 2026, which is reassuring.

• Nausea: most commonly reported, typically mild and transient
• Vomiting and diarrhoea: occur in a minority of participants, manageable with dose adjustment
• No significant cardiovascular safety signals observed in trials to date
• No increased risk of severe hypoglycaemia in non-diabetic participants
• Long-term safety data still being accrued — post-marketing surveillance will be essential

Who May Be Suitable for Orforglipron Treatment?

Based on the trial population enrolled in ATTAIN-1, orforglipron appears most appropriate for adults with a BMI of 30 or above (obesity), or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea. This mirrors the eligibility criteria used for currently approved weight loss injections in the UK. A separate arm of development targets people with type 2 diabetes, where both glucose control and weight loss are desirable treatment outcomes.

Orforglipron may be particularly well suited to individuals who have been prescribed or considered injectable GLP-1 therapy but have declined due to needle phobia. Similarly, people with mobility issues that make self-injection difficult, those with a professional or lifestyle context where discreet daily pill-taking is preferable to a weekly injection, or patients who live in areas without reliable cold chain storage could all benefit from this formulation. The fact that orforglipron does not require refrigeration is especially relevant for people who travel frequently.

However, suitability should always be determined on an individual basis by a qualified prescriber. People with a history of certain gastrointestinal conditions, those on medications that interact with GLP-1 pathways, and pregnant or breastfeeding individuals would need careful clinical assessment before starting. It is also important to note that orforglipron, like all GLP-1 medications, is intended as an adjunct to lifestyle changes — not a standalone solution. Diet, physical activity, sleep, and stress management remain foundational pillars of effective weight management.

• BMI ≥30 kg/m², or BMI ≥27 with comorbidities — mirrors current injectable eligibility
• People with needle phobia or injection site difficulties
• Individuals requiring discretion (e.g., daily tablet easier to take at work or while travelling)
• Those for whom cold chain storage is impractical
• Not suitable during pregnancy, and caution warranted in certain GI conditions — prescriber review essential

UK Availability, Regulatory Status and What Comes Next

As of mid-2026, orforglipron has not yet received regulatory approval from either the MHRA in the UK or the European Medicines Agency. Eli Lilly has indicated that an FDA submission in the United States is anticipated in the near term, and approvals in other jurisdictions — including the UK — are expected to follow if the regulatory review is successful. The pace of regulatory review for GLP-1 medications has been relatively swift in recent years, given the significant unmet need in obesity management, so optimism is warranted.

For UK patients and clinicians, the question of NHS access will also be crucial. The NICE appraisal process — which determines whether a new medicine is cost-effective enough to be funded on the NHS — can take one to two years after regulatory approval. Given the constraints on the NHS prescribing budget and the experience with tirzepatide and semaglutide, it is realistic to expect that orforglipron may initially be available only through private prescription, at least in the short term. Monitoring developments from NHS England and NICE will be important for anyone hoping to access this medication through the health service.

Private availability, once approved, would likely come through specialist weight management services and online pharmacy platforms that conduct appropriate clinical assessments. If you are currently using or considering an injectable GLP-1 and are wondering how your current treatment trajectory compares, resources like our Mounjaro week-by-week weight loss guide provide helpful context on what realistic timelines look like with existing medications.

• No MHRA or EMA approval as of mid-2026 — still in pre-registration phase
• FDA submission by Eli Lilly anticipated imminently; UK approval expected to follow
• NHS access will likely require a NICE appraisal, which may take one to two years post-approval
• Private prescribing is the most likely initial access route in the UK
• Stay informed through MHRA and NICE update channels for the latest regulatory news

Orforglipron Clinical Trial Data at a Glance

Parameter	Orforglipron 12 mg	Orforglipron 24 mg	Orforglipron 45 mg	Placebo
Trial	ATTAIN-1 (Phase 3)	ATTAIN-1 (Phase 3)	ATTAIN-1 (Phase 3)	ATTAIN-1 (Phase 3)
Weight loss at 26 weeks	~4.8%	~6.4%	~7.9%	~1.5%
Weight loss at 40 weeks	~5.8%	~7.6%	~9.4%	~1.7%
HbA1c reduction (ATTAIN-DM)	Moderate	Moderate–significant	Significant	Minimal
Route of administration	Oral tablet	Oral tablet	Oral tablet	Oral tablet
Frequency	Once daily	Once daily	Once daily	Once daily
Most common adverse events	Nausea, diarrhoea	Nausea, vomiting	Nausea, vomiting	Minimal GI events
Refrigeration required	No	No	No	No
Regulatory status (UK, 2026)	Pre-approval	Pre-approval	Pre-approval	N/A

Key Takeaways

• Orforglipron is the first truly oral, small-molecule GLP-1 receptor agonist in late-stage development for obesity — representing a genuine innovation in weight management medicine
• Phase 3 ATTAIN-1 trial data shows up to approximately 9.4% body weight reduction over 40 weeks at the 45 mg dose, which is clinically meaningful
• Weight loss is lower than that seen with injectable tirzepatide or semaglutide, but the oral format may make treatment accessible to people who cannot or will not self-inject
• Side effects are predominantly gastrointestinal and consistent with the GLP-1 drug class, with no new or unexpected safety signals in current data
• UK regulatory approval has not been granted as of mid-2026, but is anticipated within the next one to two years if FDA review proceeds as expected

When to Seek Professional Advice

If you are considering orforglipron or any weight loss medication, it is important to consult a qualified prescriber — whether a GP, specialist weight management physician, or a prescribing pharmacist — before starting or switching treatments. Do not attempt to obtain orforglipron from unregulated online sources, as the medication has not yet received approval from UK regulatory bodies and unverified products carry significant safety risks.

Seek professional advice promptly if you:

• Are currently taking a GLP-1 injectable and are considering switching to an oral alternative
• Have a BMI that may qualify you for weight loss treatment but have not yet been assessed
• Experience significant gastrointestinal symptoms on any GLP-1 medication that are affecting your quality of life
• Have type 2 diabetes and are looking for a medication that addresses both glucose control and weight management
• Are uncertain whether a new or emerging weight loss medication is appropriate for your personal health circumstances

Scientific References

1. Aronne LJ et al. (2025). Orforglipron for the Treatment of Obesity. New England Journal of Medicine. ATTAIN-1 Phase 3 Trial Results.
2. National Institute for Health and Care Excellence (NICE). Obesity: Identification, Assessment and Management. Clinical Guideline CG189.
3. Medicines and Healthcare products Regulatory Agency (MHRA). GLP-1 Receptor Agonists: Regulatory Updates and Safety Communications. GOV.UK.

Frequently Asked Questions

How long does orforglipron take to show weight loss results?

Orforglipron results in weight loss typically begin within the first four to eight weeks of treatment, with more significant reductions seen by weeks twelve to twenty. In phase 3 trials, participants lost around 7.9% of body weight by week 26, and up to approximately 9% or more by week 40 at higher doses.

Is orforglipron safe to take long term?

Orforglipron appears to be well tolerated in clinical trials conducted to date, with a side effect profile broadly similar to other GLP-1 receptor agonists. Long-term safety data beyond 40 weeks is still being gathered in ongoing phase 3 trials, and patients should discuss individual suitability with a qualified prescriber before starting treatment.

Can you take orforglipron with other medications?

Orforglipron may interact with certain medications, particularly those affecting gastric emptying or blood glucose levels. It must be taken on an empty stomach with plain water and no food for at least 30 minutes afterward. Always disclose your full medication list to your prescriber or pharmacist before starting orforglipron.

What is the dose of orforglipron for weight loss?

The orforglipron dose studied for weight loss in the ATTAIN-1 phase 3 trial ranged from 12 mg to 45 mg taken once daily, with dose escalation over several weeks. The 45 mg dose produced the greatest weight loss of approximately 9% body weight reduction, though lower doses also delivered meaningful clinical results.